Report Description Table of Contents How Are Targeted Therapies and Emerging Clinical Developments Reshaping the Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market? According to Strategic Market Research, the Global Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market was estimated at USD 0.86 billion in 2025 and is projected to reach USD 1.52 billion by 2032, expanding at a CAGR of 8.46% during 2026–2032. The projected USD 660 million increase in annual market revenue reflects demand for long-term symptom management and growing clinical investment in targeted therapies, particularly among patients requiring sustained cardiovascular treatment. High POTS Prevalence Supports Recurring Treatment Demand: According to Dysautonomia International, approximately 4.5 million Americans are estimated to live with POTS, with women representing around 82.5% of patients. The substantial patient population supports demand for ongoing symptom management. A 2025 systematic review covering 21 randomized trials and 750 patients evaluated pharmacological treatments, including beta-blockers, ivabradine, midodrine, and fludrocortisone, highlighting the continued clinical importance of established medications. Regeneron's Baloncibart Advances Targeted POTS Drug Development: Regeneron's investigational antibody baloncibart (REGN7544) represents an emerging targeted treatment opportunity. Its Phase 1 study involving 80 healthy adults demonstrated sustained blood pressure increases of approximately 5–10 mmHg. In its October 30, 2026 business update, Regeneron announced plans to present Phase 2 POTS findings in November 2026 and pursue Phase 3 development in the first half of 2027, subject to regulatory discussions. Successful clinical development could establish a differentiated prescription treatment category beyond existing symptom-directed medications. NIH's RECOVER Program Is Evaluating Treatment Effectiveness in Long COVID-Associated POTS: The NIH-funded RECOVER-AUTONOMIC program initially planned enrollment of 380 participants across 50 U.S. sites. Results from an ivabradine trial involving 181 adults showed reduced heart rates without significant overall POTS symptom improvement versus placebo. Additional November 2026 research presentations involving Gamunex-C intravenous immunoglobulin are examining alternative treatment approaches. These developments emphasize the importance of demonstrated clinical benefits in determining future prescribing and reimbursement opportunities. Immunoglobulin Research Faces Clinical Development Challenges: CSL Behring's Phase 3 investigation of Hizentra (IgPro20) for post-COVID POTS originally targeted 177 participants, but recruitment reached only 16 patients before sponsor-initiated termination, according to the Health Canada clinical trial record. The termination illustrates clinical development and recruitment risks for specialized POTS therapies, making successful trial completion and patient selection important considerations for pharmaceutical investment. Non-Invasive Neuromodulation Shows Early Clinical Potential: A 26-patient clinical study reported a standing-related heart rate increase of 17.6 bpm in the active neuromodulation group, compared with 31.7 bpm in the sham group, after two months. Although the findings remain preliminary, they support further investigation of non-pharmaceutical treatment options and potential opportunities for specialized neuromodulation technologies. Overall, the POTS Treatment Market is evolving from established symptom management toward clinically differentiated treatment options. Regeneron's baloncibart development, NIH-supported immunoglobulin research, and early neuromodulation findings represent important areas of investigation. Future commercial growth will depend on successful clinical trials, demonstrated improvements in patient symptoms, regulatory approvals, and reimbursement access. Leading and Fastest-Growing Subsegments: Clinical Adoption, Treatment Innovation, and Specialist Care By Treatment Type: Persistent Symptoms Sustain Demand for Individualized Medication Leading and Fastest-Growing Subsegment: Pharmacological Treatment Pharmacological treatment represented the largest category of the Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market, accounting for an estimated 58% share, equivalent to USD 498.8 million in 2025, and is projected to grow at a 9.00% CAGR through 2032. Medication is introduced when increased fluid and salt intake, compression garments, and graded exercise provide inadequate symptom control, or when a patient's physiological profile warrants targeted therapy. Clinicians may use beta-blockers, ivabradine, midodrine, or fludrocortisone according to symptoms and treatment goals. By Drug Class: Established Medicines and Selective Heart-Rate Control Shape Prescribing Leading Subsegment: Beta-Blockers Beta-blockers accounted for an estimated 20% of the Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market in 2025, equivalent to approximately USD 172 million, and are projected to register a CAGR of 8.00% during 2026–2032. Primarily used off-label, beta-blockers such as propranolol help control excessive heart-rate increases associated with standing and reduce the physiological effects of adrenaline surges. Their therapeutic application is particularly relevant for POTS patients experiencing pronounced tachycardia, palpitations, and related cardiovascular symptoms. Fastest-Growing Subsegment: Heart-Rate-Modulating Agents (Ivabradine) Ivabradine accounted for an estimated 9% share of the Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market in 2025, equivalent to USD 77.4 million, and is projected to register the fastest growth among drug classes, at a CAGR of 12.0% during 2026–2032. The medicine selectively inhibits the If (“funny”) current in the sinoatrial node, slowing heart rate without reducing cardiac contractility. Although primarily used for heart-rate control in cardiovascular indications, clinicians also prescribe ivabradine off-label to manage tachycardia in patients with POTS. By Care Setting: Multidisciplinary Clinics and Autonomic Centers Support Long-Term Care Leading Subsegment: Cardiology and Neurology Clinics Cardiology and neurology clinics account for an estimated 42% share of the global Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market, equivalent to USD 361.2 million in 2025, and are projected to expand at a CAGR of 8.80% during 2026–2032. Their leading position reflects the multidisciplinary nature of POTS, which involves abnormal cardiovascular responses and autonomic nervous system dysfunction. Cardiologists evaluate heart rate and blood pressure abnormalities, while neurologists assess autonomic regulation, supporting coordinated diagnosis, treatment, and long-term patient management. Fastest-Growing Subsegment: Autonomic Disorder Specialty Centers Autonomic Disorder Specialty Centers play a critical role in the Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market by supporting accurate diagnosis, subtype classification, and coordinated long-term care. Their teams combine autonomic function testing, clinical assessment, medication management, and guidance on fluid intake, exercise, and lifestyle adjustments. In 2025, Autonomic Disorder Specialty Centers accounted for an estimated 20% share, equivalent to USD 172 million, and are projected to expand at a 10.10% CAGR from 2026 to 2032, reflecting the growing importance of specialist-led POTS care. By Country: U.S. Clinical Investment and Australian Patient Recognition Shape Demand Leading Country: United States The United States accounted for an estimated 33% share of the Global POTS Treatment Market in 2025, equivalent to USD 283.8 million. The market is projected to grow at a CAGR of 8.20% during 2026–2032, reaching approximately USD 492.7 million by 2032. Its leadership is supported by an estimated 4.5 million affected individuals, based on the midpoint of Dysautonomia International's 3–6 million estimate. The NIH-funded RECOVER-AUTONOMIC initiative planned to enroll 380 participants across 50 U.S. sites, evaluating ivabradine, intravenous immunoglobulin, and coordinated care. Additionally, Regeneron's baloncibart (REGN7544) Phase 2 development is strengthening the country's position in POTS-specific pharmaceutical research. These developments support demand for established medications, specialist treatment, and emerging therapies. (Dysautonomia International; NIH RECOVER; Regeneron). Fastest-Growing Country: Australia Australia accounted for an estimated 3% share of the Global POTS Treatment Market in 2025, representing USD 25.8 million. The market is projected to register a CAGR of 10.20% during 2026–2032, reaching approximately USD 50.9 million by 2032. Growth is supported by the Australian POTS Registry, which reported findings from 500 patients, including 86.8% female participants and 32.6% with POTS following COVID-19 infection. The study also identified an average diagnostic delay of 7 years for women and 3.8 years for men, highlighting opportunities for earlier diagnosis and treatment. Furthermore, Australia's introduction of a dedicated POTS classification code, G90.81, from July 2025 is improving the identification and recording of diagnosed patients. Greater clinical recognition and improved patient identification are expected to support demand for prescription medications and long-term specialist care. (Medical Journal of Australia; IHACPA). Which Emerging Therapies and Clinical Pipeline Developments Are Reshaping the POTS Treatment Landscape? Ivabradine – Advancing Targeted Heart-Rate Management Ivabradine is receiving increased clinical attention because it selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without substantially lowering blood pressure. The NIH-supported RECOVER-AUTONOMIC platform trial is evaluating ivabradine alongside intravenous immunoglobulin (IVIG) and coordinated non-pharmacological care in adults with Long COVID-associated POTS. The randomized, double-blind research program is designed to assess symptom improvement, physical functioning, quality of life, and treatment safety. REGN7544 – Investigating a Novel Immunological Target Regeneron Pharmaceuticals is investigating REGN7544, an experimental natriuretic peptide receptor 1 (NPR1) antagonist monoclonal antibody for POTS. Its Phase II PINNACLE study (NCT06593600) enrolled 82 participants and evaluated pharmacokinetics, safety, tolerability, and changes in standing heart rate and blood pressure. The study was completed in July 2026, although outcome results were not listed in the retrieved registry information. Low-Dose Naltrexone – Exploring Fatigue and Inflammatory Pathways Low-dose naltrexone (LDN) is being investigated for persistent fatigue and potential inflammatory involvement in POTS. ClinicalTrials.gov study NCT05363514 is a registered pilot investigation planning to enroll 80 participants across three sites, with a 16-week treatment period. The study evaluates fatigue severity, quality of life, inflammatory cytokines, and orthostatic symptoms. Its estimated primary completion is June 2029. Immunoglobulin Therapies – Investigating Autoimmune-Associated POTS IVIG is being evaluated for patients with suspected immune-mediated autonomic dysfunction through the NIH RECOVER-AUTONOMIC program. Separately, CSL Behring investigated subcutaneous immunoglobulin IgPro20 (Hizentra) in a Phase III study of post-COVID POTS. However, the IgPro20 study ended in July 2025, and its trial status was subsequently recorded as closed, with results posted in April 2026. This remains an important development when assessing the clinical viability of immunoglobulin-based treatment. Pyridostigmine and Droxidopa – Additional Pharmacological Research Pyridostigmine enhances acetylcholine activity by inhibiting acetylcholinesterase and may help reduce excessive standing heart rate. It remains an off-label treatment option supported by relatively limited clinical evidence. Droxidopa, a norepinephrine precursor, is also being explored for its potential to improve vascular tone and standing tolerance, although POTS-specific controlled clinical evidence remains insufficient. Which Companies Are Shaping the Competitive Landscape of the POTS Treatment Market? Regeneron Pharmaceuticals, Inc.: Baloncibart Development Opens a Targeted Treatment Path Regeneron is an important emerging competitor through its investigational monoclonal antibody, baloncibart (REGN7544), which targets natriuretic peptide receptor 1 (NPR1). The company is investigating this biological pathway as a potential approach to managing autonomic and cardiovascular abnormalities associated with POTS. Its PINNACLE Phase II clinical trial (NCT06593600) enrolled 82 participants across 16 clinical sites in the United States and Canada. The study commenced in November 2024 and was completed in July 2026. Regeneron's October 2026 regulatory filing continued to list POTS as a Phase II indication, with clinical results identified as an upcoming milestone for Q4 2026. This program gives the company a differentiated position in the emerging biologic treatment segment. CSL Behring: Hizentra Research Highlights Immunoglobulin Development Risks CSL Behring has established a direct clinical research presence in POTS through IgPro20 (Hizentra), a subcutaneous immunoglobulin therapy investigated for post-COVID POTS. Its planned Phase III study was designed to enroll 177 adult patients, using a randomized, double-blind, placebo-controlled design to assess treatment efficacy, safety, and autonomic symptoms. The research explored whether immunomodulatory treatment could address potential immune-mediated mechanisms associated with post-infectious POTS. However, the European clinical trial registry records the study as ended on May 13, 2025, following a sponsor decision. Therefore, this program represents an important clinical development rather than an established commercial POTS treatment. Other Pharmaceutical Companies and Their Market Roles: Pfizer Inc.: Participates in the broader cardiovascular and pharmaceutical industry; no dedicated POTS-specific marketed therapy or clinical program was identified in the reviewed public disclosures. Novartis International AG: Represents a broader pharmaceutical competitor, although a dedicated POTS-specific product or clinical development program was not established in the reviewed evidence. AstraZeneca plc: Has a historical connection through Inderal (propranolol), a beta-blocker used in POTS management; it divested the global commercial rights to Atnahs Pharma in 2020, subject to specified territorial exceptions. Merck Group: Operates across pharmaceuticals and life sciences, but a dedicated POTS-specific therapeutic or clinical pipeline role was not verified. Sanofi S.A.: Maintains a substantial immunology and specialty medicine portfolio, but no dedicated POTS-specific treatment program was identified in the reviewed disclosures. Amgen Inc.: Commercializes Corlanor (ivabradine), a heart-rate-modulating medicine approved for specified heart failure indications and used off-label in selected POTS patients. Analyst Commentary: How Can Clinical Validation Expand Targeted Treatment Opportunities? The POTS treatment market presents opportunities in targeted heart-rate management, immunomodulatory therapies, and specialized autonomic care. Development of POTS-specific drugs and clinically validated treatment protocols will be critical to expanding therapeutic options and strengthening pharmaceutical market participation. Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 0.86 Billion Revenue Forecast in 2032 USD 1.52 Billion Overall Growth Rate CAGR of 8.46% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Drug Class, By Care Setting, By Geography By Treatment Type Pharmacological Treatment, Non-Pharmacological Treatment, Supportive and Adjunctive Treatment By Drug Class Beta-Blockers, Vasoconstrictors (Midodrine), Heart-Rate-Modulating Agents (Ivabradine), Other Drug Classes By Care Setting Hospitals, Cardiology and Neurology Clinics, Autonomic Disorder Specialty Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Long-term symptom management requirements, continued use of established cardiovascular medicines, clinical research into Long COVID-associated POTS, and investment in targeted drug development Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the POTS Treatment Market? A1. Growth is supported by rising POTS diagnosis, increasing demand for long-term symptom management, expanding specialist autonomic care, and clinical development of targeted cardiovascular and immunological therapies. Q2. Which treatment category holds the largest market share? A2. Pharmacological treatment leads with a 58% share, equivalent to USD 498.8 million in 2025, and is projected to grow at a CAGR of 9.00% during 2026–2032, supported by the use of beta-blockers, ivabradine, midodrine, and fludrocortisone. Q3. Why are ivabradine-based therapies gaining importance in the industry? A3. Ivabradine is projected to record the fastest drug-class CAGR of 12.00% during 2026–2032. Its ability to reduce excessive heart rate without substantially lowering blood pressure supports its use in selected POTS patients. Q4. Which care setting offers the strongest growth opportunity in the market? A4. Autonomic disorder specialty centers are projected to record the fastest care-setting CAGR of 10.10% during 2026–2032, supported by specialized autonomic testing, subtype classification, and multidisciplinary patient management. Q5. How are emerging therapies influencing the competitive landscape? A5. Regeneron's investigational baloncibart (REGN7544) is creating opportunities for targeted POTS treatment. Its Phase II PINNACLE study enrolled 82 participants and was completed in July 2026, with clinical findings identified as an upcoming milestone in the company's October 2026 update. Q6. Which region is expected to record the fastest growth in the market? A6. Asia-Pacific is projected to record the fastest regional CAGR of 10.45% during 2026–2032. Growth is supported by expanding diagnostic access, increasing recognition of autonomic disorders, and improving specialist healthcare capacity across Japan, China, India, and Australia. Sources: Regeneron – October 30, 2026 Update Identified Phase 2 Baloncibart Results in POTS as a November 2026 Milestone and Planned Phase 3 Initiation for the First Half of 2027, Subject to Regulatory Feedback Regeneron – Third-Quarter 2026 Business Update and Baloncibart Clinical Development U.S. National Institutes of Health – RECOVER-AUTONOMIC Initially Planned to Enroll 380 Participants Across 50 U.S. Sites to Evaluate Ivabradine, Intravenous Immunoglobulin, and Coordinated Non-Drug Care NIH – Clinical Trials for Long COVID–Associated Autonomic Nervous System Dysfunction NIH-Funded RECOVER Initiative – March 2026 Results From 181 Adults With Long COVID POTS Found That Ivabradine Reduced Heart Rate Without Significantly Improving Overall POTS Symptoms Compared With Placebo RECOVER – Ivabradine Trial Results Presented at the 2026 ACC Conference NIH-Funded RECOVER Initiative – October 29, 2026 Announcement Scheduled November Presentations on Gamunex-C Intravenous Immunoglobulin and Coordinated Non-Drug Care for Long COVID POTS RECOVER – November 2026 Research Presentations on IVIG and Coordinated POTS Care Government of Canada – Documents Regeneron’s Phase 2 Placebo-Controlled Study of REGN7544, an NPR1 Antagonist Antibody, in Patients With POTS Health Canada – REGN7544 Phase 2 POTS Clinical Trial Government of Canada – Lists the Phase 3 Hizentra Study in Post-COVID-19 POTS as Closed, With a Recorded Completion Date of July 11, 2025 Health Canada – Hizentra Phase 3 Post-COVID-19 POTS Trial and Study Status U.S. National Library of Medicine – Registered Low-Dose Naltrexone Study Plans to Recruit 80 POTS Patients Across Three Sites for a 16-Week Placebo-Controlled Investigation ClinicalTrials.gov – Low-Dose Naltrexone Use in Patients With POTS: NCT05363514 Australian Independent Health and Aged Care Pricing Authority – Includes POTS Among Classification Updates in ICD-10-AM Thirteenth Edition, Applicable to Hospital Separations From July 1, 2025 IHACPA – ICD-10-AM/ACHI/ACS Thirteenth Edition: Summary of Updates UK National Health Service – July 2026 Guidance Identifies Compression Clothing, Fludrocortisone, and Beta Blockers Among Options for Managing POTS Symptoms NHS – Postural Tachycardia Syndrome: Medicines and Non-Drug Management Amgen – Corlanor Prescribing Information Lists Heart Failure Indications; POTS Is Not a Listed Approved Indication Amgen – Corlanor (Ivabradine): Full Prescribing Information AstraZeneca – Completed the Divestment of Commercial Rights to Inderal and Other Established Cardiovascular Medicines to Atnahs Pharma in March 2020 AstraZeneca – Completion of Cardiovascular Medicines Divestment to Atnahs Pharma Table of Contents – Global Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Drug Class, Care Setting, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Drug Class, Care Setting, and Region Emerging Clinical Developments and Targeted POTS Treatment Opportunities Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Drug Class, and Care Setting Regional Market Share Analysis Investment Opportunities in the POTS Treatment Market Key Developments and Innovations in POTS Treatment Clinical Pipeline Developments and Strategic Partnerships High-Growth Segments for Investment Opportunities in Heart-Rate-Modulating Agents, Beta-Blockers, Vasoconstrictors, Immunoglobulin Therapies, and Neuromodulation Emerging Opportunities in Long COVID-Associated POTS Research Specialist Autonomic Care and Multidisciplinary Treatment Delivery Market Introduction Definition and Scope of the Study Overview of Postural Orthostatic Tachycardia Syndrome Market Structure and Key Findings Overview of Top Investment Pockets Clinical Importance of Long-Term Symptom Management and Cardiovascular Treatment Role of Autonomic Dysfunction Assessment and Specialist Diagnosis Impact of Long COVID-Associated POTS on Treatment Demand Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Clinical Trial and Treatment Pipeline Assessment Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Public Health Factors High POTS Prevalence and Recurring Treatment Demand Role of Beta-Blockers, Ivabradine, Midodrine, and Fludrocortisone in Symptom Management Clinical Development of Targeted Therapies and Immunoglobulin Treatments Impact of Long COVID-Associated POTS and NIH-Supported Research Emerging Role of Non-Invasive Neuromodulation Diagnostic Delays, Treatment Access, and Specialist Care Trends Global POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Pharmacological Treatment Non-Pharmacological Treatment Supportive and Adjunctive Treatment Market Analysis by Drug Class: Beta-Blockers Vasoconstrictors (Midodrine) Heart-Rate-Modulating Agents (Ivabradine) Other Drug Classes, including Fludrocortisone, Pyridostigmine, and Clonidine Market Analysis by Care Setting: Hospitals Cardiology and Neurology Clinics Autonomic Disorder Specialty Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, and Care Setting Country-Level Breakdown: United States Canada Mexico Europe POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, and Care Setting Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, and Care Setting Country-Level Breakdown: Japan China India Australia Rest of Asia-Pacific Latin America POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, and Care Setting Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa POTS Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, and Care Setting Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Regeneron Pharmaceuticals, Inc. CSL Behring Pfizer Inc. Novartis International AG AstraZeneca plc Merck Group Sanofi S.A. Amgen Inc. Abbott Laboratories Bristol Myers Squibb Teva Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Viatris Inc. Hikma Pharmaceuticals plc Competitive Landscape and Strategic Insights Benchmarking Based on Cardiovascular Drug Portfolios, Targeted Therapy Development, Clinical Trial Activity, and Specialist Treatment Access Baloncibart Clinical Development and Pipeline Positioning Immunoglobulin Therapy Research and Clinical Development Assessment Heart-Rate-Modulating Drug Portfolio Positioning Neuromodulation Research and Non-Pharmacological Treatment Development Regulatory and Clinical Trial Progress Assessment Through 2032 Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Trial and Drug Development References Market Definitions and Segmentation Criteria List of Tables Market Size by Treatment Type, Drug Class, Care Setting, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Analysis (2025), and Forecast (2026–2032) Regional Market Breakdown by Treatment Type, Drug Class, and Care Setting (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Leading and Fastest-Growing Subsegment Analysis Clinical Pipeline and Emerging Therapy Assessment Competitive Benchmarking of Leading Pharmaceutical and Biotechnology Companies Clinical Trial Assessment of Baloncibart, Immunoglobulin Therapies, and Other Investigational Treatments List of Figures Market Drivers, Challenges, Opportunities, and Restraints Global POTS Treatment Market Overview Regional Market Snapshot Competitive Landscape by Market Share Market Share by Treatment Type, Drug Class, and Care Setting (2025 vs. 2032) Regional Market Comparison Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Clinical Pipeline and Emerging Targeted Therapy Landscape Global POTS Treatment Ecosystem and Value Chain Analysis